Brewer Science Library Phone: (608) 647-6513 The following article is
published by the Brewer Science Library. Single
copies of the article may be printed for the
reader's personal research and study. Reproduction
in any other manner, format or location is
Brewer Science Library
Phone: (608) 647-6513
The following article is published by the Brewer Science Library. Single copies of the article may be printed for the reader's personal research and study. Reproduction in any other manner, format or location is expressly prohibited.
HYALURONIC ACID (HA) & CANCER
While doing a search for information about prostate cancer, a transcript was found of an article by Dr. Lance Morris, Use of Hyaluronic Acid to Enhance High Dose Intravenous Vitamin C in the Treatment of Cancer & Other Diseases, which he had presented in November of 2004, and can be found at: (www.smartlifeforun.org/2004/11/newsletter.html). He discussed several prostate cancer cases as well as a breast cancer case in which he utilized intravenous vitamin C at 75 grams along with 5 cc of a low molecular weight 1% hyaluronic acid solution and obtained positive results. Dr. Morris is associated with the Wholistic Family Medicine Clinic (520-322-8122) in Tucson, Arizona.
Early Cancer Work with HA by Dr. Falk:
Basics of Dr. Falk’s Use of HA with Cancer U.S. Patent #5827834:
Dr. Falk noted in his patent the research demonstrating that in the cancer patient, although the macrophages were activated, they were not able to cause destruction to cancer cells; something was blocking them. As he stated, when macrophages were removed from cancer patients, and then washed and cultured, they performed normally. In his patent, he noted that in 1989 it was shown that the excessive levels of prostaglandins around the cancer cells, were what caused the macrophages to be unable to take action against the cancer cells. In both test tube and animal studies, when the levels of prostaglandins were reduced by the use of non-steroidal anti-inflammatory (NSAIDS) drugs, such as indomethacin and naproxen, better control of cancer tissue growth could be effected. The problem was that NSAIDS produce significant side effects that patients were often unable to tolerate.
The protocol he developed used hyaluronic acid as a carrier substance to more effectively reach the cancer cell’s receptors (discussed further in this article), with NSAIDS, vitamin C, and small amounts of an appropriate chemotherapeutic agent. He utilized intravenous, intratumor, intraperitoneal or intrapleural use of this therapy for his patients. This protocol resulted in better penetration of the drugs into the tumor cells. Hyaluronic acid helps to carry the agents further into the solid tumors increasing the amount of tumor destruction. His patent application includes interesting case histories and results of 40 patients with cancer or other health problems receiving his unique therapy.
One of his case histories demonstrates how effective hyaluronic acid can be as a carrier to increase penetration of whatever is given with it. The dieuretc, furosemide (Lasix), sometimes becomes ineffective at increasing urine output in patients that for various reasons have a poor kidney response. One example shows that in the previous 12 hours, a 40 mg dose of Lasix only resulted in 400 ml of urine, whereas when the same dose of Lasix administered intravenously in hyaluronic acid, was able to produce 2,600 ml of urine in the same patient. He states that HA with the Lasix can result in a 3 to 5 fold increase in urine output.
Cancer Cell Receptors CD44 & RHAMM and HA:
The fact that CD44 and RHAMM receptors are expressed in greater numbers on cancer cells offers an avenue of transporting and targeting anti-cancer agents to tumors, metastatic lesions and lymphatic tissues. Although Dr. Falk may have been one of the first doctors to recognize and utilize this capacity of hyaluronic acid, this function of HA is being utilized more and more today.
This important receptor, CD44, comes in several forms, a short form that is found on normal cells and longer variations that occur on cancer cells. The CD44 receptor is situated within the phospholipid membranes of the cells, with a part of it extending into the interior cell cytoplasm. There it interacts with the intracellular machinery involved in cell movement, which can lead to cancer cells breaking off and creating metastases in other areas of the body. Experimental research with the longer receptor form of CD44 demonstrated that when it was inserted into benign tumor cells, they became aggressive, metastasizing cancer cells. The enzyme in the body that breaks down hyaluronic acid is hyaluronidase. This enzyme also reduces the long form of CD44 into the short form, which is the normal and immobile form. Research with mice given human breast cancer demonstrated significant tumor shrinkage upon IV treatment with the hyaluronidase enzyme.
HA Combined With Anti-Cancer Drugs:
Instilled HA to Treat Bladder Cystitis:
Urine Test for Bladder Cancer Measures HA-Haase:
HA-HAase Tumor Markers for Prostate Cancer:
Hyaluronic acid- Butyrate Esters in Cancer Research:
Links to Other Important Hyaluronic Acid Information:
Hyaluronic Acid:Not With Cancer, Never With Aromatase Inhibitors
This is an important newsletter article to read from the Denver Naturopathic Clinic.
How to Live 100 Years Without Growing Old, book by Bill Sardi.
Hyaluronan Promotes the Malignant Phenotype, mini review by Bryan P. Toole, Glycobiology, 2002, Vol. 12, No. 3 37R-42R Oxford University Press
DISCLAIMER: The information contained on this website has not been evaluated by the Food & Drug Administration. It is not meant to diagnose, treat, cure or prevent any disease. Individuals suffering from any disease or illness should consult with a physician or health care professional. The Brewer Science Library offers Dr. Brewer's writings for information purposes only and will assume no responsibility or liability for the use of any of the information we offer whether written by Dr. Brewer or others.
1998-2006, Brewer Science Library
Problems with this site? Contact the webmaster.